[登录] [免费注册]
试剂仪器网
发布求购
位置：首页 > 产品库 > SRX3207
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
SRX3207
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
SRX3207图片
CAS NO:2254693-15-5
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
SRX3207 是具有口服活性的、首创的 Syk/PI3K 双抑制剂，其对 Syk 和 PI3Kα 的 IC50 值分别为 10.7 nM 和 861 nM。SRX3207 缓解抗肿瘤免疫抑制。
Cas No.2254693-15-5
分子式C29H29N7O3S
分子量555.65
溶解度DMSO : 5 mg/mL (9.00 mM; Need ultrasonic)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression[1][2].

SRX3207 (10 μmol/L) is able to block p-AKT at concentration[1].SRX3207 has sufficient solubility in water (43 μmol/L)[1].

SRX3207 (10 mg/kg, orally) increases antitumor immune response[1].

[1]. Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020.
[2]. Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764.